BACKGROUND: From April to July 2009, the United States experienced a wave of influenza A (H1N1)pdm09 virus (H1N1pdm09) infection. The majority of the deaths during that period occurred in persons <65 years of age with underlying medical conditions. OBJECTIVE: To describe the epidemiology of H1N1pdm09-associated deaths in the US during the fall of 2009. METHODS: We collected demographic, medical history, and cause of death information on a nationally representative, stratified random sample of 323 H1N1pdm09-associated deaths that occurred during September 1-October 31, 2009. RESULTS: Data were available for 302/323 (93%) deaths. Most cases (74%) were 18-64 years of age and had ≥ 1 underlying medical condition (72%). Among cases aged <18 years, 16/43 (37%) had a chronic lung disease, and 15/43 (35%) a neurological disorder; among cases aged ≥ 18 years, 94/254 (37%) had a chronic lung disease and 84/254 (33%) had a metabolic disorder. The median number of days between symptom onset and death was six among children (range, 1-48) and 12 among adults (range, 0-109). Influenza antiviral agents were prescribed for 187/268 (70%) of cases, but only 48/153 (31%) received treatment within 2 days of illness onset. CONCLUSIONS: The characteristics of H1N1pdm09 deaths identified during the fall of 2009 were similar to those occurring April-July 2009. While most cases had conditions that were known to increase the risk for severe outcomes and were recommended to receive antiviral therapy, a minority of cases received antivirals early in the course of illness.
BACKGROUND: From April to July 2009, the United States experienced a wave of influenza A (H1N1)pdm09 virus (H1N1pdm09) infection. The majority of the deaths during that period occurred in persons <65 years of age with underlying medical conditions. OBJECTIVE: To describe the epidemiology of H1N1pdm09-associated deaths in the US during the fall of 2009. METHODS: We collected demographic, medical history, and cause of death information on a nationally representative, stratified random sample of 323 H1N1pdm09-associated deaths that occurred during September 1-October 31, 2009. RESULTS: Data were available for 302/323 (93%) deaths. Most cases (74%) were 18-64 years of age and had ≥ 1 underlying medical condition (72%). Among cases aged <18 years, 16/43 (37%) had a chronic lung disease, and 15/43 (35%) a neurological disorder; among cases aged ≥ 18 years, 94/254 (37%) had a chronic lung disease and 84/254 (33%) had a metabolic disorder. The median number of days between symptom onset and death was six among children (range, 1-48) and 12 among adults (range, 0-109). Influenza antiviral agents were prescribed for 187/268 (70%) of cases, but only 48/153 (31%) received treatment within 2 days of illness onset. CONCLUSIONS: The characteristics of H1N1pdm09 deaths identified during the fall of 2009 were similar to those occurring April-July 2009. While most cases had conditions that were known to increase the risk for severe outcomes and were recommended to receive antiviral therapy, a minority of cases received antivirals early in the course of illness.
Authors: R G Pebody; E McLean; H Zhao; P Cleary; S Bracebridge; K Foster; A Charlett; P Hardelid; P Waight; J Ellis; A Bermingham; M Zambon; B Evans; R Salmon; J McMenamin; B Smyth; M Catchpole; Jm Watson Journal: Euro Surveill Date: 2010-05-20
Authors: Anthony E Fiore; David K Shay; Karen Broder; John K Iskander; Timothy M Uyeki; Gina Mootrey; Joseph S Bresee; Nancy J Cox Journal: MMWR Recomm Rep Date: 2009-07-31
Authors: Ashley L Fowlkes; Paul Arguin; Matthew S Biggerstaff; Jacqueline Gindler; Dianna Blau; Seema Jain; Roseline Dhara; Joe McLaughlin; Elizabeth Turnipseed; John J Meyer; Janice K Louie; Alan Siniscalchi; Janet J Hamilton; Ariane Reeves; Sarah Y Park; Deborah Richter; Matthew D Ritchey; Noelle M Cocoros; David Blythe; Susan Peters; Ruth Lynfield; Lesha Peterson; Jannifer Anderson; Zack Moore; Robin Williams; Lisa McHugh; Carmen Cruz; Christine L Waters; Shannon L Page; Christie K McDonald; Meredith Vandermeer; Kirsten Waller; Utpala Bandy; Timothy F Jones; Lesley Bullion; Valoree Vernon; Kathryn H Lofy; Thomas Haupt; Lyn Finelli Journal: Clin Infect Dis Date: 2011-01-01 Impact factor: 9.079
Authors: Kathy Hancock; Vic Veguilla; Xiuhua Lu; Weimin Zhong; Eboneé N Butler; Hong Sun; Feng Liu; Libo Dong; Joshua R DeVos; Paul M Gargiullo; T Lynnette Brammer; Nancy J Cox; Terrence M Tumpey; Jacqueline M Katz Journal: N Engl J Med Date: 2009-09-10 Impact factor: 91.245
Authors: T W Hennessy; D Bruden; L Castrodale; K Komatsu; L M Erhart; D Thompson; K Bradley; D R O'Leary; J McLaughlin; M Landen Journal: Epidemiol Infect Date: 2015-06-29 Impact factor: 2.451
Authors: Barbara Rath; Tim Conrad; Puja Myles; Maren Alchikh; Xiaolin Ma; Christian Hoppe; Franziska Tief; Xi Chen; Patrick Obermeier; Bron Kisler; Brunhilde Schweiger Journal: Expert Rev Anti Infect Ther Date: 2017-05-12 Impact factor: 5.091